Cancer medicine · 2026
A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.
СтатьяРандомизированное исследованиеКлиническое исследование II фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xicheng Wang, Yanhong Deng, Yanqiao Zhang, Tianshu Liu, Xianglin Yuan, Jianwei Yang, Tao Zhang, Aimin Zang, Yu Liu, Li Huang, Feng Ye, Hong Zong, Yi Ba, Isabelle Klauck, Jean-Claude Vedovato, Mélanie Groc, Angela Guo, Jian Li, Lin Shen
Аннотация
BACKGROUND: Colorectal cancer (CRC) is a major health burden globally and in China, where 3%-5% of cases involve the BRAFV600E mutation, which is associated with aggressive disease and therefore a poor prognosis. Although the combination of encorafenib and cetuximab has demonstrated improved survival in BRAFV600E mutant metastatic CRC (mCRC), such treatments remain unavailable as chemotherapy-free options in China.
METHODS: The NAUTICAL CRC, a Phase II study in Chinese patients with BRAFV600E mutant metastatic CRC, includes a Safety Lead-In (SLI) phase for tolerability assessment and a randomized phase comparing encorafenib/cetuximab vs. irinotecan-based regimens, potentially bridging the treatment gap and evaluating safety, efficacy, and Quality of Life (QoL) outcomes in this Chinese population.
RESULTS: No dose-limiting toxicity was identified in the SLI phase (N = 10). In the Randomized phase (N = 97), the Doublet arm demonstrated superior progression-free survival (PFS) of 4.2 months vs. 2.5 months in the Control arm (hazard ratio [HR]: 0.37, p = 0.0004) and longer overall survival (OS) of 11.6 months vs. 8.2 months (HR: 0.55). Treatment-related adverse events were common but more severe in the Control arm. QoL measures consistently favored the Doublet arm, showing improved health status and reduced deterioration risk.
CONCLUSIONS: This NAUTICAL CRC Phase II study showed that the combination of encorafenib and cetuximab offers significant clinical benefits, improving PFS and OS, while providing manageable safety and important QoL advantages, making it a valuable treatment option for Chinese patients with previously treated BRAFV600E mutant mCRC.
TRIAL REGISTRATION: Clinical study registration number: NCT05004350.
METHODS: The NAUTICAL CRC, a Phase II study in Chinese patients with BRAFV600E mutant metastatic CRC, includes a Safety Lead-In (SLI) phase for tolerability assessment and a randomized phase comparing encorafenib/cetuximab vs. irinotecan-based regimens, potentially bridging the treatment gap and evaluating safety, efficacy, and Quality of Life (QoL) outcomes in this Chinese population.
RESULTS: No dose-limiting toxicity was identified in the SLI phase (N = 10). In the Randomized phase (N = 97), the Doublet arm demonstrated superior progression-free survival (PFS) of 4.2 months vs. 2.5 months in the Control arm (hazard ratio [HR]: 0.37, p = 0.0004) and longer overall survival (OS) of 11.6 months vs. 8.2 months (HR: 0.55). Treatment-related adverse events were common but more severe in the Control arm. QoL measures consistently favored the Doublet arm, showing improved health status and reduced deterioration risk.
CONCLUSIONS: This NAUTICAL CRC Phase II study showed that the combination of encorafenib and cetuximab offers significant clinical benefits, improving PFS and OS, while providing manageable safety and important QoL advantages, making it a valuable treatment option for Chinese patients with previously treated BRAFV600E mutant mCRC.
TRIAL REGISTRATION: Clinical study registration number: NCT05004350.